FilingReader Intelligence

Junshi Bio's cancer drug advances in China approval

August 8, 2025 at 05:03 PM UTCBy FilingReader AI

Shanghai Junshi Biosciences Co announced China's drug regulator accepted its supplemental application for toripalimab combined with disitamab vedotin as first-line treatment for advanced urothelial carcinoma.

The RC48-C016 study showed the combination significantly improved progression-free survival and overall survival versus standard chemotherapy.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

HKEX:1877Hong Kong Exchange

News Alerts

Get instant email alerts when Junshi BIO publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →